TULOBUTEROL

Details

Stereochemistry	RACEMIC
Molecular Formula	C12H18ClNO
Molecular Weight	227.73
Optical Activity	( + / - )
Defined Stereocenters	0 / 1
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

CC(C)(C)NCC(O)C1=C(Cl)C=CC=C1

InChI

InChIKey=YREYLAVBNPACJM-UHFFFAOYSA-N

InChI=1S/C12H18ClNO/c1-12(2,3)14-8-11(15)9-6-4-5-7-10(9)13/h4-7,11,14-15H,8H2,1-3H3

HIDE SMILES / InChI

Molecular Formula	C12H18ClNO
Molecular Weight	227.73
Charge	0
Count

Stereochemistry	RACEMIC
Additional Stereochemistry	No
Defined Stereocenters	0 / 1
E/Z Centers	0
Optical Activity	( + / - )

Description
Sources: http://www.rad-ar.or.jp/siori/english/kekka.cgi?n=1078
Curator's Comment: description was created based on several sources, including: http://www.mylan.co.jp/-/media/MylanJP/documents/epd_products/interview_updated/if_hokunalin.pdf

Tulobuterol is a long-acting beta2-adrenergic receptor agonist. Tulobuterol has almost no effects on blood pressure and heart rate and is highly selective for the tracheal muscle. It is indicated to improve symptoms such as respiratory distress caused by airway obstruction of bronchial asthma, bronchitis, chronic obstructive pulmonary disease (COPD) and emphysema. Serious side effects detected were: tremor, palpitations and serum potassium level decrease.

CNS Activity

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Beta-2 adrenergic receptor 203 Target ID: CHEMBL210 Sources: http://www.mylan.co.jp/-/media/MylanJP/documents/epd_products/interview_updated/if_hokunalin.pdf \| https://www.ncbi.nlm.nih.gov/pubmed/15212190	Agonist 2678

Conditions

Condition	Modality	Highest Phase	Product
Bronchial asthma 50 Sources: http://www.rad-ar.or.jp/siori/english/kekka.cgi?n=1078	Palliative	Approved 8429	Hokunalin Approved Use It is usually used to improve symptoms such as respiratory distress caused by airway obstruction of bronchial asthma, acute bronchitis, chronic bronchitis, or emphysema. Launch Date 1981
Bronchitis 51 Sources: http://www.rad-ar.or.jp/siori/english/kekka.cgi?n=1078	Palliative	Approved 8429	Hokunalin Approved Use It is usually used to improve symptoms such as respiratory distress caused by airway obstruction of bronchial asthma, acute bronchitis, chronic bronchitis, or emphysema. Launch Date 1981
Chronic obstructive pulmonary disease 174 Sources: http://hokunalin.jp/patient/introduction/effect.html	Palliative	Approved 8429	Hokunalin Approved Use It is usually used to improve symptoms such as respiratory distress caused by airway obstruction of bronchial asthma, acute bronchitis, chronic bronchitis, COPD or emphysema. Launch Date 1981
Emphysema 13 Sources: http://www.mylan.co.jp/-/media/mylanjp/documents/epd_products/20170220%20hokunalin1ds0.1_r7.pdf	Palliative	Approved 8429	Hokunalin Approved Use It is usually used to improve symptoms such as respiratory distress caused by airway obstruction of bronchial asthma, acute bronchitis, chronic bronchitis, or emphysema. Launch Date 1981

PubMed

Title	Date	PubMed
Induction and reduction of muscle tremor upon acute and repeated administration of the beta 2-agonists terbutaline, salbutamol and tulobuterol.	1987 Dec	2893778
[Long-acting beta 2-stimulants].	2001 Oct	11676141
[Development of transdermal formulation of tulobuterol for the treatment of bronchial asthma].	2002 Jan	11828751
[Patchs: the success of transdermal administration].	2004 Apr	15222181
High-performance liquid chromatography electrospray ionization mass spectrometry determination of tulobuterol in rabbit's plasma.	2005 Feb 7	15664761
Determination of beta-agonist residues in bovine urine using liquid chromatography-tandem mass spectrometry.	2005 Jan-Feb	15759725
Differential effects of short-acting beta2-agonists on human granulocyte functions.	2006	16272820
The use of patch formulation of tulobuterol, a long-acting beta2-adrenoreceptor agonist, in the treatment of severe pediatric asthma.	2006 Jun	16802779
Immunology and homeopathy. 3. Experimental studies on animal models.	2006 Jun	16786046
Comparison of the effects of tulobuterol patch and salmeterol in moderate to severe asthma.	2006 Nov	17042908
Improvement of pulmonary function and dyspnea by tiotropium in COPD patients using a transdermal beta(2)-agonist.	2007	17049894
[The efficacy and safety of tulobuterol tape in mild and moderate persistent asthma patients].	2007 Jan	17331388
Clinical efficacy of the transdermal tulobuterol patch in patients with chronic obstructive pulmonary disease: a comparison with slow-release theophylline.	2008	18344636
Characterization of monolithic matrix patch system containing tulobuterol.	2008 Aug	18787793
Anti-inflammatory effects and clinical efficacy of theophylline and tulobuterol in mild-to-moderate chronic obstructive pulmonary disease.	2008 Dec	18983928
[Simultaneous determination of nine beta-agonist residues in animal derived foods by ultra performance liquid chromatography-tandem mass spectrometry].	2008 Nov	19253549
Cough and transdermal long-acting beta2 agonist in Japan.	2008 Oct	18573645
Effects of the addition of Beta2-agonist tulobuterol patches to inhaled corticosteroid in patients with asthma.	2009 Dec	19700936
Detection of tulobuterol crystal in transdermal patches using terahertz pulsed spectroscopy and imaging.	2009 Jun	19618670
Chemical mapping of tulobuterol in transdermal tapes using microscopic laser Raman spectroscopy.	2009 Mar	19348338
Comparison of adherence and efficacy between inhaled salmeterol and transdermal tulobuterol patch in elderly patients with chronic obstructive pulmonary disorder.	2009 May	19470012
Comparative study of skin permeation profiles between brand and generic tulobuterol patches.	2010	20930390
Characterization and release behaviors of porous PCL/Eudragit RS microcapsules containing tulobuterol.	2010 Apr 1	20034769
[Determination of fifteen beta-agonists in animal urine by high performance liquid chromatography-tandem mass spectrometry].	2010 Aug	21261043
Effect of porous silica on sustained release behaviors of pH sensitive pluronic F127/poly(acrylic acid) hydrogels containing tulobuterol.	2010 Oct 15	20621457

Patents

Sample Use Guides

In Vivo Use Guide

In general, for adults and children aged 9 or older, apply 2 mg of the tape to the chest, back, or upper arm, once daily. For children aged 6 months to 2 years, apply 0.5 mg of the tape to the chest, back, or upper arm, once daily. For children aged 3 to 8 years, apply 1 mg of the tape to the chest, back, or upper arm, once daily. This preparation contains 2 mg of the active ingredients in a piece of tape.

Route of Administration: Transdermal

In Vitro Use Guide

The binding rate of 14 C-tulobuterol hydrochloride to the serum protein (human) was 28.14 ± 1.53% in vitro (Mean ± S.E.).

Substance Class	Chemical Created by `admin` on `Fri Dec 15 15:14:02 GMT 2023` Edited by `admin` on `Fri Dec 15 15:14:02 GMT 2023`
Record UNII	591I9SU0F7
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

TULOBUTEROL

Official Name

English

tulobuterol [INN]

Common Name

English

Tulobuterol [WHO-DD]

Common Name

English

TULOBUTEROL [JAN]

Common Name

English

.ALPHA.-((TERT-BUTYLAMINO)METHYL)-O-CHLOROBENZYL ALCOHOL

Common Name

English

NSC-758643

Code

English

TULOBUTEROL [MI]

Common Name

English

Classification Tree Code System Code

NCI_THESAURUS

C319